ACR-368 endometrial cancer Phase 2: 62.5% ORR in OncoSignature+ patients; ACR-2316 IND cleared

Acrivon Therapeutics, Inc.

Confirmed ORR of 62.5% (95% CI 30.4-86.5) in prospectively-selected OncoSignature+ endometrial cancer patients who progressed on anti-PD-1.
Statistically significant segregation of responders vs OncoSignature- arm (p=0.009); all responding patients still on therapy; mDoR not yet reached (~6 months).
Endometrial cancer anticipated as first potential accelerated approval opportunity for ACR-368.
FDA cleared IND for ACR-2316 (dual WEE1/PKMYT1 inhibitor); clinical sites activated; first-in-human dosing expected Q4 2024.
Cash of $220.4M (June 30, 2024) expected to fund operations into H2 2026; guidance reiterated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.